

A revolutionary advancement in skin cancer detection

verisante.com
TSX-V: VRS
OTCQX: VRSEF
FRANKFURT: V3T



Verisante Aura™ is a novel, multimodality imaging and spectroscopy system designed to aid in the detection of skin cancer. This system provides valuable information about the chemical composition of the skin quickly and non-invasively. Verisante Aura™ scans for 21 spectral markers instantly; thus providing immediate, accurate results.

Early Detection Saves Lives

Jointly developed by the BC Cancer Agency and the University of British Columbia, and refined and tested at the Skin Care Centre at Vancouver General Hospital, this patent protected technology has already been used in a human clinical study spanning six years on approximately 1,000 lesions. Preliminary results published in 2008 showed the Verisante Aura™ found every case of melanoma in 274 lesions flagged for biopsy.

Verisante Aura™ will help to automate the current process of diagnosis, allowing rapid scanning of the 20 – 40 skin lesions on “at risk” individuals. No longer will patients need to suffer through long wait times to see a dermatologist, as scans may be accomplished quickly by trained technicians or assistants. Verisante Aura™ will greatly aid healthcare professionals, delivering significant clinical impact through improved patient outcomes and reduced wait times.

The Verisante product development team is led by award-winning pioneers in the field of cancer imaging. In addition, the Company is proud to have world renowned experts in cancer detection involved with our technical and medical team.

Aura™ has been approved for sale in Canada, the EU and Australia.

ISO 13485: 2003



The Facts on Skin Cancer

- Skin cancer is the most common form of cancer, and most rapidly increasing
- Every hour, one person in the United States dies of melanoma
- 50% of people over the age of 65 in the US will be affected by skin cancer
- One in six Canadians will develop skin cancer during their lifetime
- Survival rate of patients where the disease is detected early is 99%
- Survival rate of patients with advanced stage skin cancer is 15%
- The treatment of advanced stage melanoma costs 2200% more than early stage melanoma
- The annual treatment cost of treating skin cancer in the United States is estimated at USD \$3.0 billion



The platform technology behind Verisante Aura™ is fully extensible to detection systems for other cancers.

Verisante Core™ uses an endoscopic attachment to aid in the detection of lung, colon, cervical, and other cancers.

The results of a pilot study on lung cancer detection were published in the *Journal of Thoracic Oncology* in July 2011. The results of the study indicate that Verisante's system technology could set a new standard for the early detection of lung cancer.

The Canadian Cancer Society recently named the technology behind Core™ as one of the "Top 10 breakthroughs of 2011".

Contact

Verisante Technology, Inc.
306 - 2309 West 41st Avenue
Vancouver BC V6M 2A3

Tel 604 605 0507
Fax 604 605 0508

info@verisante.com
verisante.com
TSX-V: VRS
OTCQX: VRSEF
FRANKFURT: V3T



Revenue Model

The Verisante Aura™ will require the use of a disposable end cap that must be replaced after each use for health / sanitary reasons. Thus, in addition to revenue from initial sales of the device, the Company will also have a recurring revenue stream.

Investment Highlights

- Revolutionary, patent-protected, platform technology
- Applicable to several forms of cancer
- Clear regulatory pathway that will result in significant early revenue
- Imaging device for the safe detection of skin cancer now approved for sale in Canada, the EU, and Australia
- Recurring revenue model
- Strategic alliances with leading institutions
- World class scientific capability
- Project management led by experienced, award-winning pioneers
- Medical and technical team led by renowned experts
- Highly qualified management
- Strong, independent board
- Raised \$9.5 million in 2011, ensuring sufficient funding through commercialization
- Aura™ named as a top technology innovation, and received a "Best of What's New" award from *Popular Science* (2011)
- Core™ technology named by the Canadian Cancer Society as one of the "Top 10 breakthroughs of 2011"

Company Profile

Verisante Technology, Inc. is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Company's device for skin cancer detection, Aura™, is approved for sale in Canada, the EU, and Australia. Verisante's Aura™ and Core™ (for lung, colon and cervical cancer detection) devices utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device.

This exclusive platform technology allows Verisante to develop compact, non-invasive cancer detection devices that offer immediate results for many of the most common cancers.

Verisante Technology, Inc. was recognized as a TSX Venture 50® company in 2012. TSX Venture 50 is a trade-mark of TSX Inc. and is used under license.

This fact sheet contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.